Nama's AI scorecard currently rates Oruka Therapeutics Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does ORKA report earnings?

Oruka Therapeutics's next scheduled report is on Nov 11, 2026. Analysts expect EPS of -$0.62.

What is the ORKA price target?

The median analyst price target from 12 analysts is $155.50, with a range of $117.00 – $200.00.

Is ORKA Shariah compliant?

Nama's AAOIFI-style screen reads Oruka Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Oruka Therapeutics (ORKA)

Healthcare · Biotechnology · NASDAQ

Oruka Therapeutics (ORKA) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $6.81B and a free-cash-flow yield of -1.5%. Nama's AI scorecard rates it Sell, 2.7 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 2.7/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Leading · +181.1% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-11.0%

How far the last close sits under the highest price of the past five years.

Market cap	$6.81B
Trailing P/E	—
Price / book	5.7
Price / sales	—
FCF yield	-1.5%
Dividend yield	—
Gross margin	0.0%
Operating margin	0.0%
Net margin	0.0%
Revenue growth (YoY)	—
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	-0.1
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

ORKA earnings

Next report: Nov 11, 2026 (Q3 2026, EPS estimate -$0.62). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 10, 2026	-$0.55	-$0.50	-10.0%	$0
Q1 2026	May 13, 2026	-$0.48	-$0.54	+11.1%	$0
Q4 2025	Mar 12, 2026	-$0.45	-$0.62	+27.4%	$0
Q3 2025	Nov 12, 2025	-$0.55	-$0.52	-5.8%	$0

ORKA analyst price target

Median target $155.50 from 12 analysts, ranging $117.00 – $200.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live ORKA data on Nama Insights →

ORKA FAQ

Is ORKA a buy?: Nama's AI scorecard currently rates Oruka Therapeutics Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does ORKA report earnings?: Oruka Therapeutics's next scheduled report is on Nov 11, 2026. Analysts expect EPS of -$0.62.
What is the ORKA price target?: The median analyst price target from 12 analysts is $155.50, with a range of $117.00 – $200.00.
Is ORKA Shariah compliant?: Nama's AAOIFI-style screen reads Oruka Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.